{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T17:39:15Z","timestamp":1779903555706,"version":"3.53.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:00:00Z","timestamp":1728604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:00:00Z","timestamp":1728604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI14C1135"],"award-info":[{"award-number":["HI14C1135"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2021R1F1A1057106"],"award-info":[{"award-number":["NRF-2021R1F1A1057106"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ildong Pharmaceutical Company","award":["Ildong-LCDI-2018-0143"],"award-info":[{"award-number":["Ildong-LCDI-2018-0143"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-024-00800-3","type":"journal-article","created":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T15:01:57Z","timestamp":1728658917000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["GR113808, a serotonin receptor 4 antagonist, prevents high-fat-diet-induced obesity, fatty liver formation, and insulin resistance in C57BL\/6J mice"],"prefix":"10.1186","volume":"25","author":[{"given":"Min Hee","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Jeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo-Jae","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoung-Kon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,11]]},"reference":[{"issue":"10290","key":"800_CR1","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell EE, Wong VW-S, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397(10290):2212\u201324.","journal-title":"Lancet"},{"issue":"3","key":"800_CR2","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s00535-017-1415-1","volume":"53","author":"Y Sumida","year":"2018","unstructured":"Sumida Y, Yoneda M. Current and future pharmacological therapies for NAFLD\/NASH. J Gastroenterol. 2018;53(3):362\u201376.","journal-title":"J Gastroenterol"},{"key":"800_CR3","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388\u2013402.","DOI":"10.1016\/j.jhep.2015.11.004"},{"issue":"15","key":"800_CR4","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/j.febslet.2015.05.054","volume":"589","author":"R El-Merahbi","year":"2015","unstructured":"El-Merahbi R, L\u00f6ffler M, Mayer A, Sumara G. The roles of peripheral serotonin in metabolic homeostasis. FEBS Lett. 2015;589(15):1728\u201334.","journal-title":"FEBS Lett"},{"issue":"5","key":"800_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1462399407000245","volume":"9","author":"DD Lam","year":"2007","unstructured":"Lam DD, Heisler LK. Serotonin and energy balance: molecular mechanisms and implications for type 2 diabetes. Expert Rev Mol Med. 2007;9(5):1\u201324.","journal-title":"Expert Rev Mol Med"},{"issue":"10","key":"800_CR6","doi-asserted-by":"publisher","first-page":"e1000229","DOI":"10.1371\/journal.pbio.1000229","volume":"7","author":"N Paulmann","year":"2009","unstructured":"Paulmann N, Grohmann M, Voigt J-P, Bert B, Vowinckel J, Bader M, et al. Intracellular serotonin modulates insulin secretion from pancreatic \u03b2-cells by protein serotonylation. PLoS Biol. 2009;7(10):e1000229.","journal-title":"PLoS Biol"},{"issue":"5770","key":"800_CR7","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1126\/science.1123842","volume":"312","author":"M Lesurtel","year":"2006","unstructured":"Lesurtel M, Graf R, Aleil B, Walther DJ, Tian Y, Jochum W, et al. Platelet-derived serotonin mediates liver regeneration. Science. 2006;312(5770):104\u20137.","journal-title":"Science"},{"key":"800_CR8","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.phrs.2018.06.015","volume":"140","author":"H Wu","year":"2019","unstructured":"Wu H, Denna TH, Storkersen JN, Gerriets VA. Beyond a neurotransmitter: the role of serotonin in inflammation and immunity. Pharmacol Res. 2019;140:100\u201314.","journal-title":"Pharmacol Res"},{"issue":"10","key":"800_CR9","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1177\/153537020322801003","volume":"228","author":"T Kadowaki","year":"2003","unstructured":"Kadowaki T, Hara K, Yamauchi T, Terauchi Y, Tobe K, Nagai R. Molecular mechanism of insulin resistance and obesity. Exp Biol Med (Maywood). 2003;228(10):1111\u201317.","journal-title":"Exp Biol Med (Maywood)"},{"key":"800_CR10","doi-asserted-by":"publisher","first-page":"1160053","DOI":"10.3389\/fmed.2023.1160053","volume":"10","author":"S Wu","year":"2023","unstructured":"Wu S, Wang X, Xing W, Li F, Liang M, Li K, et al. An update on animal models of liver fibrosis. Front Med (Lausanne). 2023;10:1160053.","journal-title":"Front Med (Lausanne)"},{"key":"800_CR11","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/978-1-0716-0385-7_14","volume":"2128","author":"PF Pedro","year":"2020","unstructured":"Pedro PF, Tsakmaki A, Bewick GA. The glucose tolerance test in mice. Methods Mol Biol. 2020;2128:207\u201316.","journal-title":"Methods Mol Biol"},{"issue":"1","key":"800_CR12","doi-asserted-by":"publisher","first-page":"4824","DOI":"10.1038\/s41467-018-07287-7","volume":"9","author":"W Choi","year":"2018","unstructured":"Choi W, Namkung J, Hwang I, Kim H, Lim A, Park HJ, et al. Serotonin signals through a gut-liver axis to regulate hepatic steatosis. Nat Commun. 2018;9(1):4824.","journal-title":"Nat Commun"},{"key":"800_CR13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.applanim.2014.11.010","volume":"163","author":"CM Moody","year":"2015","unstructured":"Moody CM, Makowska IJ, Weary DM. Testing three measures of mouse insensibility following induction with isoflurane or carbon dioxide gas for a more humane euthanasia. Appl Anim Behav Sci. 2015;163:183\u201387.","journal-title":"Appl Anim Behav Sci"},{"issue":"4","key":"800_CR14","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 2001;25(4):402\u20138.","journal-title":"Methods"},{"issue":"3","key":"800_CR15","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1172\/JCI34275","volume":"118","author":"C Postic","year":"2008","unstructured":"Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest. 2008;118(3):829\u201338.","journal-title":"J Clin Invest"},{"issue":"4","key":"800_CR16","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.livres.2018.12.001","volume":"2","author":"YK Lee","year":"2018","unstructured":"Lee YK, Park JE, Lee M, Hardwick JP. Hepatic lipid homeostasis by peroxisome proliferator-activated receptor gamma 2. Liver Res. 2018;2(4):209\u201315.","journal-title":"Liver Res"},{"issue":"2","key":"800_CR17","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s11154-013-9283-3","volume":"15","author":"B Lee","year":"2014","unstructured":"Lee B, Shao J. Adiponectin and energy homeostasis. Rev Endocr Metab Disord. 2014;15(2):149\u201356.","journal-title":"Rev Endocr Metab Disord"},{"issue":"Suppl 1","key":"800_CR18","first-page":"S50","volume":"23","author":"H Huang","year":"2008","unstructured":"Huang H, Park PH, McMullen MR, Nagy LE. Mechanisms for the anti-inflammatory effects of adiponectin in macrophages. J Gastroenterol Hepatol. 2008;23(Suppl 1):S50\u20133.","journal-title":"J Gastroenterol Hepatol"},{"issue":"10","key":"800_CR19","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1002\/eji.1830111013","volume":"11","author":"JM Austyn","year":"1981","unstructured":"Austyn JM, Gordon S. F4\/80, a monoclonal antibody directed specifically against the mouse macrophage. Eur J Immunol. 1981;11(10):805\u201315.","journal-title":"Eur J Immunol"},{"issue":"12","key":"800_CR20","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384(12):1113\u201324.","journal-title":"N Engl J Med"},{"issue":"42","key":"800_CR21","doi-asserted-by":"publisher","first-page":"30028","DOI":"10.1074\/jbc.274.42.30028","volume":"274","author":"I Shimomura","year":"1999","unstructured":"Shimomura I, Bashmakov Y, Horton JD. Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J Biol Chem. 1999;274(42):30028\u201332.","journal-title":"J Biol Chem"},{"issue":"5","key":"800_CR22","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1210\/jc.2010-2129","volume":"96","author":"P Pettinelli","year":"2011","unstructured":"Pettinelli P, Videla LA. Up-regulation of PPAR-gamma mRNA expression in the liver of obese patients: an additional reinforcing lipogenic mechanism to SREBP-1c induction. J Clin Endocrinol Metab. 2011;96(5):1424\u201330.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"800_CR23","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1172\/JCI119248","volume":"99","author":"H Shimano","year":"1997","unstructured":"Shimano H, Horton JD, Shimomura I, Hammer RE, Brown MS, Goldstein JL. Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells. J Clin Invest. 1997;99(5):846\u201354.","journal-title":"J Clin Invest"},{"key":"800_CR24","doi-asserted-by":"crossref","unstructured":"Fang DL, Wan Y, Shen W, Cao J, Sun ZX, Yu HH, et al. Endoplasmic reticulum stress leads to lipid accumulation through upregulation of SREBP-1c in normal hepatic and hepatoma cells. Mol Cell Biochem. 2013;381(1-2):127\u201337.","DOI":"10.1007\/s11010-013-1694-7"},{"issue":"4","key":"800_CR25","doi-asserted-by":"publisher","first-page":"699","DOI":"10.2337\/diabetes.48.4.699","volume":"48","author":"J Rieusset","year":"1999","unstructured":"Rieusset J, Andreelli F, Auboeuf D, Roques M, Vallier P, Riou JP, et al. Insulin acutely regulates the expression of the peroxisome proliferator-activated receptor-gamma in human adipocytes. Diabetes. 1999;48(4):699\u2013705.","journal-title":"Diabetes"},{"issue":"3","key":"800_CR26","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.cell.2011.06.034","volume":"146","author":"TR Peterson","year":"2011","unstructured":"Peterson TR, Sengupta SS, Harris TE, Carmack AE, Kang SA, Balderas E, et al. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell. 2011;146(3):408\u201320.","journal-title":"Cell"},{"issue":"9","key":"800_CR27","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1194\/jlr.M015263","volume":"52","author":"EJ Jung","year":"2011","unstructured":"Jung EJ, Kwon SW, Jung BH, Oh SH, Lee BH. Role of the AMPK\/SREBP-1 pathway in the development of orotic acid-induced fatty liver. J Lipid Res. 2011;52(9):1617\u201325.","journal-title":"J Lipid Res"},{"issue":"11","key":"800_CR28","first-page":"1","volume":"51","author":"YR Kim","year":"2019","unstructured":"Kim YR, Lee EJ, Shin KO, Kim MH, Pewzner-Jung Y, Lee YM, et al. Hepatic triglyceride accumulation via endoplasmic reticulum stress-induced SREBP-1 activation is regulated by ceramide synthases. Exp Mol Med. 2019;51(11):1\u201316.","journal-title":"Exp Mol Med"},{"issue":"1","key":"800_CR29","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.bbrc.2009.02.131","volume":"382","author":"M Awazawa","year":"2009","unstructured":"Awazawa M, Ueki K, Inabe K, Yamauchi T, Kaneko K, Okazaki Y, et al. Adiponectin suppresses hepatic SREBP1c expression in an AdipoR1\/LKB1\/AMPK dependent pathway. Biochem Biophys Res Commun. 2009;382(1):51\u201356.","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"800_CR30","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1007\/s13679-014-0124-9","volume":"3","author":"SS Pereira","year":"2014","unstructured":"Pereira SS, Alvarez-Leite JI. Low-grade inflammation, obesity, and diabetes. Curr Obes Rep. 2014;3(4):422\u201331.","journal-title":"Curr Obes Rep"},{"key":"800_CR31","doi-asserted-by":"publisher","first-page":"112789","DOI":"10.1016\/j.biopha.2022.112789","volume":"148","author":"ME Shaker","year":"2022","unstructured":"Shaker ME. The contribution of sterile inflammation to the fatty liver disease and the potential therapies. Biomed Pharmacother. 2022;148:112789.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"800_CR32","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1053\/j.gastro.2018.06.083","volume":"155","author":"A Mansouri","year":"2018","unstructured":"Mansouri A, Gattolliat CH, Asselah T. Mitochondrial dysfunction and signaling in chronic liver diseases. Gastroenterology. 2018;155(3):629\u201347.","journal-title":"Gastroenterology"},{"issue":"18","key":"800_CR33","doi-asserted-by":"publisher","first-page":"10697","DOI":"10.1074\/jbc.271.18.10697","volume":"271","author":"E Hu","year":"1996","unstructured":"Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem. 1996;271(18):10697\u2013703.","journal-title":"J Biol Chem"},{"issue":"1","key":"800_CR34","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1530\/eje.1.01821","volume":"152","author":"C Pagano","year":"2005","unstructured":"Pagano C, Soardo G, Esposito W, Fallo F, Basan L, Donnini D, et al. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol. 2005;152(1):113\u201318.","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"800_CR35","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1172\/JCI29126","volume":"116","author":"T Kadowaki","year":"2006","unstructured":"Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006;116(7):1784\u201392.","journal-title":"J Clin Invest"},{"issue":"1","key":"800_CR36","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1172\/JCI200317797","volume":"112","author":"A Xu","year":"2003","unstructured":"Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest. 2003;112(1):91\u2013100.","journal-title":"J Clin Invest"},{"issue":"3","key":"800_CR37","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1124\/jpet.111.181834","volume":"339","author":"S Haub","year":"2011","unstructured":"Haub S, Ritze Y, Ladel I, Saum K, Hubert A, Spruss A, et al. Serotonin receptor type 3 antagonists improve obesity-associated fatty liver disease in mice. J Pharmacol Exp Ther. 2011;339(3):790\u201398.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"800_CR38","doi-asserted-by":"publisher","first-page":"dmm048922","DOI":"10.1242\/dmm.048922","volume":"14","author":"M Ko","year":"2021","unstructured":"Ko M, Kamimura K, Owaki T, Nagoya T, Sakai N, Nagayama I, et al. Modulation of serotonin in the gut-liver neural axis ameliorates the fatty and fibrotic changes in non-alcoholic fatty liver. Dis Model Mech. 2021;14(3):dmm048922.","journal-title":"Dis Model Mech"},{"issue":"7","key":"800_CR39","doi-asserted-by":"publisher","first-page":"dmm049612","DOI":"10.1242\/dmm.049612","volume":"15","author":"T Owaki","year":"2022","unstructured":"Owaki T, Kamimura K, Ko M, Nagayama I, Nagoya T, Shibata O, et al. Involvement of the liver-gut peripheral neural axis in nonalcoholic fatty liver disease pathologies via hepatic HTR2A. Dis Model Mech. 2022;15(7):dmm049612.","journal-title":"Dis Model Mech"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-024-00800-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-024-00800-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-024-00800-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T03:20:28Z","timestamp":1728703228000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-024-00800-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,11]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["800"],"URL":"https:\/\/doi.org\/10.1186\/s40360-024-00800-3","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,11]]},"assertion":[{"value":"31 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were carried out in accordance with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the U.S. National Institutes of Health and were approved by the Animal Ethics Committee of the LeeGilYa Cancer and Diabetes Institute (LCDI-2021-0079).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not appicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"76"}}